focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nano Regulatory News (ONT)

Share Price Information for Oxford Nano (ONT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 108.20
Bid: 108.20
Ask: 108.60
Change: -3.30 (-2.96%)
Spread: 0.40 (0.37%)
Open: 112.80
High: 112.80
Low: 107.00
Prev. Close: 111.50
ONT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission to Trading on the London Stock Exchange

7 Nov 2023 08:30

RNS Number : 5252S
Oxford Nanopore Technologies plc
07 November 2023
 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

FOR IMMEDIATE RELEASE

 

7 NOVEMBER 2023

 

Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company")

 

Admission to Trading on the London Stock Exchange

 

Further to the announcement on 6 November 2023, Oxford Nanopore Technologies plc announces that 120,000 ordinary shares have today been admitted to the standard listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange under the ticker 'ONT'.

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:  ir@nanoporetech.com

Media:  media@nanoporetech.com

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

www.nanoporetech.com

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSEAPFXEFPDFEA
Date   Source Headline
3rd Oct 20225:00 pmRNSIssue of Equity and Total Voting Rights
29th Sep 20229:00 amRNSDirector/PDMR Shareholding
14th Sep 202211:00 amRNSDirector/PDMR Shareholding
13th Sep 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Sep 20227:00 amRNSInterim results for the period ended 30 June 2022
12th Sep 20224:30 pmRNSOxford Nanopore to present at upcoming conferences
1st Sep 20226:30 pmRNSIssue of Equity and Total Voting Rights
24th Aug 20227:00 amRNSNotice of Results
11th Aug 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Aug 20225:30 pmRNSIssue of Equity and Total Voting Rights
12th Jul 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jul 20227:00 amRNSSale and leaseback of headquarters building
1st Jul 20225:16 pmRNSIssue of Equity and Total Voting Rights
30th Jun 20227:15 amRNSDuncan Tatton-Brown appointed as Non-Exec Chair
23rd Jun 20224:30 pmRNSResult of AGM
13th Jun 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Jun 20224:00 pmRNSIssue of Equity and Total Voting Rights
31st May 20226:30 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSONT releases Remora:most comprehensive methylation
20th May 20227:00 amRNSOxford Nanopore announces tech updates
19th May 20229:06 amRNSONT opens user conference, rich science programme
13th May 20227:00 amRNSONT chosen for comprehensive human genome program
11th May 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
3rd May 20224:00 pmRNSIssue of Equity and Total Voting Rights
12th Apr 20226:15 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:00 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSPublication of Annual Report and Notice of AGM
6th Apr 20221:00 pmRNSBlock listing Interim Review
5th Apr 202211:00 amRNSDirector/PDMR Shareholding
4th Apr 20222:00 pmRNSGenomics England expands Nanopore use in cancer
1st Apr 20225:00 pmRNSIssue of Equity and Total Voting Rights
1st Apr 20227:00 amRNSAgreement
30th Mar 20222:00 pmRNSONT shows new high-accuracy, high-output chemistry
24th Mar 20227:00 amRNSNanopore sequencing profiles TB: FIND evaluation
23rd Mar 20222:02 pmRNSOxford Nanopore releases Short Fragment Mode
22nd Mar 20227:00 amRNSPreliminary Results and Guidance Update
11th Mar 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 20227:03 amRNSPublication: Nanopore IDs >50 genetic diseases
1st Mar 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Feb 20227:00 amRNSNotice of Results
11th Feb 20225:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Feb 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Jan 20223:00 pmRNSAppointment of Senior Independent Director
18th Jan 20221:00 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSFastest human genome sequence uses Oxford Nanopore
11th Jan 20226:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Jan 202212:00 pmRNSUpdate to FY21 revenue guidance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.